Fig. 7: SRPK1 expression is a prognostic factor associated with EGFR expression in NSCLC patients. | Oncogene

Fig. 7: SRPK1 expression is a prognostic factor associated with EGFR expression in NSCLC patients.

From: Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer

Fig. 7

A Representative images of IHC staining of EGFR in sections from NSCLC patients (n = 59); scale bars: 20 μm. B Quantification of EGFR IHC staining; data represent the mean ± SD and whiskers represent 5 and 95 percentiles. C Correlation between SRPK1 and EGFR (Pearson’s chi-squared (χ2) test; the number of NSCLC patients is shown). D Kaplan-Meier curves used to estimate NSCLC patient PFS in the high- or low-EGFR expression groups (Log-rank test). E Clinical stage and TNM classifications of high- and low- SRPK1 expression groups (Pearson’s chi-squared (χ2) test; the number of NSCLC patients is shown). F Spearman rank analysis used to verify the correlation between SRPK1 and PFS, T classification or EGFR. The correlation coefficients are shown in the panel below. G Forest plots showing the association of characteristics with PFS in NSCLC cases. The significant variables (P < 0.1) in univariate analysis were analyzed using multivariate regression. HR > 1 indicates increased risk (decreased survival), and HR < 1 indicates decreased risk (increased survival). *P < 0.05, **P < 0.01 and ***P < 0.001.

Back to article page